GLP-1: indexed trial records
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
This page carries 12 of the 25,817 records the literature query returned for GLP-1, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.
Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.
At a glance
- Class
- Incretin receptor agonists
- Receptor targets as recorded
- GLP-1 receptor
- Records indexed here
- 12
- Records returned by the query
- 25,817
- Publication years covered
- 2012–2024
- Query retrieved
- 2026-10-12
Shape of the indexed record set
| Record class | Records |
|---|---|
| Phase 2 | 1 |
| Review or synthesis | 6 |
| Not a registered trial record | 5 |
| Study model as assigned | Records |
|---|---|
| rodent | 6 |
| other | 5 |
| human trial | 1 |
Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.
Endpoint coverage
| Endpoint | Records for this compound | Records across all compounds in scope |
|---|---|---|
| Body weight and adiposity | 7 | 108 |
| Glycaemic control | 7 | 117 |
| Cardiovascular | 1 | 30 |
| Renal | 1 | 10 |
| Hepatic | 0 | 9 |
| Neurological | 1 | 18 |
3 of the 12 records here carry no subject heading from any endpoint set used on this site, so they appear under no endpoint.
Derived record-set tier
Limited human evidence
(INFERRED, derived from record counts)
Basis: 1 interventional human trial record among 12 indexed records.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of
study quality or of consensus, and it does not rank one compound above another.
What the corpus does not carry for this compound
- Identity fields with no source retrieved: uniprot_id, sequence.
- Reported half-life: no source retrieved, so the value reads Unknown.
- Amounts reported in the cited literature: no row recorded.
- Adverse effects reported in the cited literature: no row recorded.
- Long-form mechanism: not written, because no source was read in full.
- Records the query returned that this corpus does not carry: 25,805.
An absent row records the absence of a retrieved report, never the absence of the thing itself.
Application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
The records
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 5 | pmid:30293770 | 2018 | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet (London, England) · Clinical Trial, Phase II, Multicenter Study | human trial | Humans; Diabetes Mellitus, Type 2; Weight Loss; Gastric Inhibitory Polypeptide; Blood Glucose; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome |
Review or synthesis — 6 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:39289339 | 2024 | Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Signal transduction and targeted therapy · Research Support, Non-U.S. Gov't, review-article | other | Animals; Humans; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor |
| 2 | pmid:31422062 | 2019 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials The lancet. Diabetes & endocrinology · Meta-Analysis, Research Support, Non-U.S. Gov't | other | Humans; Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Treatment Outcome; Randomized Controlled Trials as Topic; Glucagon-Like Peptide-1 Receptor Agonists |
| 3 | pmid:31767182 | 2019 | Glucagon-like peptide 1 (GLP-1) Molecular metabolism · Research Support, Non-U.S. Gov't, review-article | other | Humans; Diabetes Mellitus, Type 2; Obesity; Gastric Inhibitory Polypeptide; Insulin; Glucose; Blood Glucose; Receptors, Glucagon |
| 4 | pmid:29617641 | 2018 | Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell metabolism · Research Support, Non-U.S. Gov't, Review | rodent | Animals; Humans; Mice; Rats; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Weight Gain |
| 11 | pmid:22236411 | 2012 | Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ (Clinical research ed.) · Meta-Analysis, research-article | other | Venoms; Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents |
| 12 | pmid:22945360 | 2012 | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature reviews. Endocrinology · Review | other | Venoms; Animals; Humans; Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Hypoglycemic Agents; Treatment Outcome |
Not a registered trial record — 5 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 6 | pmid:25109781 | 2015 | The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents International journal of obesity (2005) · Research Support, Non-U.S. Gov't, research-article | rodent | Colon; Animals; Mice, Inbred C57BL; Mice; Rats; Rats, Wistar; Propionates; Gastrointestinal Hormones |
| 7 | pmid:26308095 | 2015 | Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of medicinal chemistry · Journal Article | rodent | Cell Line; Animals; Swine; Swine, Miniature; Humans; Mice, Obese; Rats, Sprague-Dawley; Crystallography, X-Ray |
| 8 | pmid:24467746 | 2014 | GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody Endocrinology · Journal Article | rodent | Duodenum; Cell Line; Venoms; Animals; Mice, Inbred C57BL; Mice, Knockout; Haplorhini; Humans |
| 9 | pmid:25202980 | 2014 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | rodent | Hypothalamus; Paraventricular Hypothalamic Nucleus; Neurons; Vagus Nerve; Animals; Mice, Transgenic; Mice; Rats |
| 10 | pmid:22190648 | 2012 | Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2 Diabetes · Research Support, Non-U.S. Gov't, research-article | rodent | Colon; Animals; Mice, Inbred C57BL; Mice; Calcium; GTP-Binding Protein alpha Subunits, Gi-Go; Fatty Acids, Volatile; Receptors, G-Protein-Coupled |
Where this page sits
Receptor targets
All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.
Review status
- Review tier
- High impact
- State
- Pending qualified review
- Compiled by
- automated pipeline
- Qualified clinical review
- None on record
Why this tier was assigned
- 1 indexed record(s) are interventional human trials
- the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus
Checks the pipeline performed
- every cited source id resolves to a sources[] row on the entity
- every identifier is a well-formed PMID or DOI
- study model derived only from assigned MeSH headings and publication types
- banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
- unknown values render as the literal word Unknown
Checks the pipeline did not perform
- no full text was read
- no clinical appraisal of any study
- no assessment of whether the indexed set is representative of the literature
A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.
Sources
- PubChem Compound Summary for CID 16133831, Glucagon-Like Peptide 1. PubChem, National Library of Medicine (2026). pubchem:16133831
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:glp-1
- Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (London, England) (1987). pmid:2890903
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of clinical investigation (1993). pmid:8423228
- The physiology of glucagon-like peptide 1. Physiological reviews (2007). pmid:17928588
- Glucagon-like peptide 1 (GLP-1). Mol Metab (2019). pmid:31767182
- A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996). pmid:8538742
- Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2012). pmid:22190648
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006). pmid:17098089
- Biology of incretins: GLP-1 and GIP. Gastroenterology (2007). pmid:17498508
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism (2018). pmid:29617641
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The lancet. Diabetes & endocrinology (2019). pmid:31422062
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The lancet. Diabetes & endocrinology (2021). pmid:34425083